Syk Inhibition in Ischemic Stroke
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Ischemic stroke is a major global public health concern. Antiplatelet therapies are a mainstay of treatment. There remains a clinical need to prevent stroke when possible and to minimize neurological damage with minimal bleeding when stroke has occurred. That is why it is particularly exciting to see the work by van Eeuwijk et al1 from the group of Bernhard Nieswandt in this issue. Based on a compelling rationale of the role of nonreceptor protein tyrosine kinase Syk in platelet activation, van Eeuwijk et al report the use of a novel oral Syk inhibitor BI1002494 for prevention and treatment of ischemic stroke in a well-established mouse model.
See accompanying article on page 1247
Platelet activation at the sites of ruptured atherosclerotic plaques results …